|

New Biomarkers and Therapeutic Targets in Osteoporosis Via Omics Technologies

RECRUITINGSponsored by National and Kapodistrian University of Athens
Actively Recruiting
SponsorNational and Kapodistrian University of Athens
Started2024-07-03
Est. completion2024-10-15
Eligibility
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06525688

Summary

This study aims to discover novel biomarkers and therapeutic targets for osteoporosis through the use of advanced omics technologies, including proteomics and metabolomics. By analyzing bone and plasma samples from patients with osteoporosis, the research seeks to understand the underlying mechanisms of the disease and identify potential diagnostic and therapeutic biomarkers.

Eligibility

Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Postmenopausal Female Patients with osteoporotic subcapital femoral neck fracture (Arm 1)
* Postmenopausal Female Patients with hip osteoarthritis that will undergo Total Hip Replacement (Arm 2)

Exclusion Criteria:

* Patients that have undergone before osteoporotic fractures
* Patients with severe cardiovascular, pulmonary, autoimmune, or urinary system conditions

Conditions4

ArthritisOsteoporosis FractureOsteoporosis, PostmenopausalOsteoporosis, Severe

Browse More Trials

Arthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.